Artemis Investment Management LLP Has $160.86 Million Stock Position in AbbVie Inc. $ABBV

Artemis Investment Management LLP decreased its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 10.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 703,998 shares of the company's stock after selling 78,703 shares during the period. AbbVie accounts for 1.9% of Artemis Investment Management LLP's portfolio, making the stock its 5th largest position. Artemis Investment Management LLP's holdings in AbbVie were worth $160,857,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. LMG Wealth Partners LLC increased its position in shares of AbbVie by 1.9% during the fourth quarter. LMG Wealth Partners LLC now owns 22,165 shares of the company's stock valued at $5,064,000 after acquiring an additional 417 shares in the last quarter. Cornerstone Planning Group LLC grew its position in AbbVie by 31.0% in the 4th quarter. Cornerstone Planning Group LLC now owns 1,637 shares of the company's stock worth $358,000 after purchasing an additional 387 shares during the period. Composition Wealth LLC boosted its stake in shares of AbbVie by 6.0% during the 4th quarter. Composition Wealth LLC now owns 62,487 shares of the company's stock worth $14,278,000 after acquiring an additional 3,534 shares during the last quarter. Golden Road Advisors LLC boosted its stake in shares of AbbVie by 6.1% during the 4th quarter. Golden Road Advisors LLC now owns 1,092 shares of the company's stock worth $250,000 after acquiring an additional 63 shares during the last quarter. Finally, Capital Investment Counsel LLC boosted its stake in shares of AbbVie by 0.4% during the 4th quarter. Capital Investment Counsel LLC now owns 48,010 shares of the company's stock worth $10,970,000 after acquiring an additional 171 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ABBV shares. Bank of America upgraded shares of AbbVie from a "neutral" rating to a "buy" rating and set a $234.00 price target on the stock in a research note on Thursday. Barclays began coverage on shares of AbbVie in a research note on Thursday, February 19th. They set an "overweight" rating and a $275.00 target price on the stock. Morgan Stanley lifted their target price on shares of AbbVie from $270.00 to $278.00 and gave the company an "overweight" rating in a research note on Thursday. Cantor Fitzgerald restated an "overweight" rating and set a $240.00 target price on shares of AbbVie in a research note on Thursday. Finally, Wall Street Zen cut shares of AbbVie from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 11th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $252.90.

Insider Activity at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of the company's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares of the company's stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the sale, the executive vice president directly owned 38,137 shares of the company's stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q1 earnings beat and guidance lift — AbbVie topped Q1 estimates, raised its 2026 outlook and said immunology drugs (Skyrizi, Rinvoq) are offsetting Humira declines. This is the core positive catalyst supporting analyst upgrades. Seeking Alpha: AbbVie hikes 2026 outlook BioSpace: AbbVie tops Q1, raises outlook
• Positive Sentiment: Sell‑side upgrades and higher price targets — Multiple firms raised ratings/targets after the results (Morgan Stanley to $278, Canaccord to $265, Guggenheim reaffirm/ $249 PT, Bank of America upgraded to Buy/$234, Cantor reiterated Overweight/$240). These lifts signal renewed analyst conviction in AbbVie’s post‑Humira pivot. Benzinga: analyst moves InsiderMonkey: BofA upgrade
• Positive Sentiment: Skyrizi competitive defense — AbbVie outlined how Skyrizi will respond to new J&J plaque‑psoriasis rival Icotyde, reinforcing confidence in market share retention for a key growth driver. FiercePharma: Skyrizi defense
• Neutral Sentiment: Corporate R&D/community engagement — AbbVie awarded the AbbVie Biotech Innovators prize to RIME Therapeutics (Quebec), signalling long‑term commitment to immunology innovation, but limited near‑term financial impact. GlobeNewswire: RIME award
• Negative Sentiment: Investors remain jittery despite the beat — WSJ coverage and market commentary highlight that, while results were strong, concerns over Humira erosion, execution risk on acquisitions/pipeline strategy, and valuation keep sentiment cautious and likely drove selling pressure. YouTube/WSJ: Investors still worried
• Negative Sentiment: Pipeline trimming and insider selling — The company discontinued a cancer candidate (noted in Q1 coverage) and recent disclosures show insiders sold shares, which can weigh on near‑term sentiment. BioSpace: discontinued candidate
• Negative Sentiment: Small analyst estimate cuts and mixed institutional flows — Erste trimmed FY2026/27 EPS modestly; recent large institutional portfolio shifts (some big sellers) add uncertainty to demand. These are headwinds for the stock near term. MarketBeat: analyst/flows summary

AbbVie Trading Down 2.2%

Shares of NYSE:ABBV opened at $206.63 on Friday. The company has a market capitalization of $365.36 billion, a price-to-earnings ratio of 101.79, a PEG ratio of 0.76 and a beta of 0.38. AbbVie Inc. has a 12 month low of $176.57 and a 12 month high of $244.81. The firm's 50-day moving average is $214.55 and its 200 day moving average is $221.60.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 911.57%. The firm's revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.46 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 14.21 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio is presently 340.89%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.